BR112014027165A2 - antagonistas de st2l e métodos de uso - Google Patents

antagonistas de st2l e métodos de uso

Info

Publication number
BR112014027165A2
BR112014027165A2 BR112014027165A BR112014027165A BR112014027165A2 BR 112014027165 A2 BR112014027165 A2 BR 112014027165A2 BR 112014027165 A BR112014027165 A BR 112014027165A BR 112014027165 A BR112014027165 A BR 112014027165A BR 112014027165 A2 BR112014027165 A2 BR 112014027165A2
Authority
BR
Brazil
Prior art keywords
methods
antagonists
st2l
st2l antagonists
fragments
Prior art date
Application number
BR112014027165A
Other languages
English (en)
Inventor
Healy Catherine
Luo Jinquan
Wheeler John
Duffy Karen
Hall Leroy
Tornetta Mark
Naso Michael
Pratta Michael
Fursov Natalie
Malaviya Ravi
Lamb Roberta
Wu Sheng-Jiun
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112014027165A2 publication Critical patent/BR112014027165A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Abstract

abstract the present invention relates to st2l antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing. ------------------------------------------------------ resumo patente de invenção "antagonistas de st2l e métodos de uso". a presente invenção refere-se a antagonistas de st2l, a polinucleotídeos que codificam os antagonistas, ou fragmentos dos mesmos, e a métodos para produzir e usar os mesmos.
BR112014027165A 2012-04-30 2013-04-29 antagonistas de st2l e métodos de uso BR112014027165A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261640238P 2012-04-30 2012-04-30
US201261640407P 2012-04-30 2012-04-30
US13/798,226 US9212227B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
US13/798,204 US9090694B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists
PCT/US2013/038637 WO2013165894A2 (en) 2012-04-30 2013-04-29 St2l antagonists and methods of use

Publications (1)

Publication Number Publication Date
BR112014027165A2 true BR112014027165A2 (pt) 2017-07-18

Family

ID=49477497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027165A BR112014027165A2 (pt) 2012-04-30 2013-04-29 antagonistas de st2l e métodos de uso

Country Status (37)

Country Link
US (4) US9212227B2 (pt)
EP (2) EP2844292B1 (pt)
JP (3) JP6283354B2 (pt)
KR (2) KR102147140B1 (pt)
CN (2) CN104411333B (pt)
AR (1) AR090909A1 (pt)
AU (2) AU2013256645B2 (pt)
BR (1) BR112014027165A2 (pt)
CA (1) CA2871948C (pt)
CL (1) CL2014002955A1 (pt)
CO (1) CO7240389A2 (pt)
CR (1) CR20140488A (pt)
CY (1) CY1122308T1 (pt)
DK (1) DK2844292T3 (pt)
EA (2) EA201891264A3 (pt)
EC (1) ECSP14025178A (pt)
ES (1) ES2755094T3 (pt)
HK (1) HK1208182A1 (pt)
HR (1) HRP20191884T1 (pt)
HU (1) HUE045864T2 (pt)
IL (2) IL235401B (pt)
LT (1) LT2844292T (pt)
MX (2) MX358134B (pt)
MY (1) MY166062A (pt)
NI (1) NI201400125A (pt)
NZ (3) NZ729913A (pt)
PE (1) PE20150641A1 (pt)
PH (2) PH12014502435A1 (pt)
PL (1) PL2844292T3 (pt)
PT (1) PT2844292T (pt)
RS (1) RS59511B1 (pt)
SG (2) SG11201407028WA (pt)
SI (1) SI2844292T1 (pt)
TW (3) TWI687440B (pt)
UA (1) UA118336C2 (pt)
UY (1) UY34774A (pt)
WO (1) WO2013165894A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
KR101791430B1 (ko) * 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3623B1 (ar) * 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA034834B1 (ru) 2013-03-15 2020-03-26 Ридженерон Фармасьютикалз, Инк. Антагонисты il-33 и их применение
CA2936366A1 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
US10040859B2 (en) 2014-04-21 2018-08-07 The Children's Hospital Of Philadelphia Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody
AU2015280436A1 (en) * 2014-06-23 2017-02-02 Bionomics, Inc. Antibodies that bind LGR4
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
CA2978431C (en) 2015-03-02 2023-10-24 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
CN108026172B (zh) * 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
WO2017124110A1 (en) * 2016-01-14 2017-07-20 Anaptysbio, Inc. Inhibition of allergic reaction using an il-33 inhibitor
WO2018045210A1 (en) * 2016-09-02 2018-03-08 Therapeutics Lp 180 Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
EP3506920A4 (en) * 2016-09-02 2020-05-27 180 Therapeutics LP METHOD OF TREATING SYSTEMIC FIBROSIS USING A BISPECIFIC ANTIBODY AGAINST IL-33 AND TNF
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
EP3957752A3 (en) 2017-04-13 2022-06-15 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
CN113286814A (zh) * 2018-10-31 2021-08-20 德里尼亚公司 多价调节性t细胞调节子
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
US20220380450A1 (en) 2019-11-04 2022-12-01 Medimmune Limited Methods of using il-33 antagonists
CA3158366A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
BR112022019937A2 (pt) 2020-04-06 2022-12-13 Medimmune Ltd Tratamento de síndrome do desconforto respiratório agudo com antagonistas de ligação de eixo de il-33
KR20230010691A (ko) 2020-05-12 2023-01-19 치아타이 티안큉 파마수티컬 그룹 주식회사 St2 항원 결합 단백질
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023160610A1 (en) * 2022-02-24 2023-08-31 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
ATE399855T1 (de) 1996-10-10 2008-07-15 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AU2002248184C1 (en) * 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
CN1934072A (zh) * 2004-01-30 2007-03-21 派普林生物脂股份有限公司 治疗和载体分子
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2006055347A2 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
NZ596834A (en) 2006-08-18 2013-06-28 Novartis Ag Prlr-specific antibody and uses thereof
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
JP2010527936A (ja) * 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
US8817596B2 (en) 2009-01-09 2014-08-26 Futurewei Technologies, Inc. Protecting ingress and egress of a label switched path
US7879978B2 (en) * 2009-03-31 2011-02-01 Centocor Ortho Biotech, Inc. Macaca fascicularis ST2L
ES2708124T3 (es) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedimiento para preparar moléculas heteromultiméricas
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
KR101791430B1 (ko) * 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
EP2552961B1 (en) 2010-03-30 2017-12-20 Janssen Biotech, Inc. Humanized il-25 antibodies
RU2684724C2 (ru) 2010-04-09 2019-04-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CN103562224B (zh) 2011-02-23 2017-08-22 弗·哈夫曼-拉罗切有限公司 针对人il33r的抗体及其用途
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2

Also Published As

Publication number Publication date
AU2017202610B2 (en) 2019-06-13
EP3597219A1 (en) 2020-01-22
AR090909A1 (es) 2014-12-17
NZ729913A (en) 2018-07-27
CR20140488A (es) 2015-01-12
IL254569B (en) 2020-10-29
US20130287777A1 (en) 2013-10-31
US10450377B2 (en) 2019-10-22
HUE045864T2 (hu) 2020-01-28
DK2844292T3 (da) 2019-10-21
MX358134B (es) 2018-08-06
PH12018501839A1 (en) 2020-09-14
WO2013165894A2 (en) 2013-11-07
EP2844292A4 (en) 2016-05-25
EA031047B1 (ru) 2018-11-30
HK1208182A1 (en) 2016-02-26
EP2844292B1 (en) 2019-08-21
CL2014002955A1 (es) 2015-01-16
KR20200037886A (ko) 2020-04-09
TW201345923A (zh) 2013-11-16
IL254569A0 (en) 2017-11-30
HRP20191884T1 (hr) 2020-02-07
TW201730216A (zh) 2017-09-01
TWI700299B (zh) 2020-08-01
JP6622274B2 (ja) 2019-12-18
MX2018009430A (es) 2020-09-02
US9212227B2 (en) 2015-12-15
AU2017202610A1 (en) 2017-05-11
CA2871948C (en) 2020-09-08
EA201891264A2 (ru) 2018-11-30
CN104411333B (zh) 2017-04-26
JP2019162136A (ja) 2019-09-26
EA201491996A1 (ru) 2015-04-30
RS59511B1 (sr) 2019-12-31
NZ740221A (en) 2019-11-29
LT2844292T (lt) 2019-11-25
CN104411333A (zh) 2015-03-11
EA201891264A3 (ru) 2019-02-28
US9951137B2 (en) 2018-04-24
EP2844292A2 (en) 2015-03-11
CO7240389A2 (es) 2015-04-17
US9090694B2 (en) 2015-07-28
US20170066831A1 (en) 2017-03-09
SI2844292T1 (sl) 2020-02-28
WO2013165894A3 (en) 2014-03-27
US20190062439A1 (en) 2019-02-28
NI201400125A (es) 2016-11-30
NZ702136A (en) 2017-03-31
AU2013256645B2 (en) 2017-06-08
IL235401A0 (en) 2014-12-31
TWI687440B (zh) 2020-03-11
ES2755094T3 (es) 2020-04-21
CA2871948A1 (en) 2013-11-07
KR20150008152A (ko) 2015-01-21
US20130336980A1 (en) 2013-12-19
JP6283354B2 (ja) 2018-02-21
AU2013256645A1 (en) 2014-11-13
TW202019969A (zh) 2020-06-01
JP2015516817A (ja) 2015-06-18
TWI589588B (zh) 2017-07-01
PE20150641A1 (es) 2015-05-11
KR102147140B1 (ko) 2020-08-25
MY166062A (en) 2018-05-22
UY34774A (es) 2013-11-29
SG11201407028WA (en) 2015-01-29
CY1122308T1 (el) 2021-01-27
PL2844292T3 (pl) 2020-03-31
JP2018064560A (ja) 2018-04-26
IL235401B (en) 2020-10-29
PT2844292T (pt) 2019-11-26
CN107098973A (zh) 2017-08-29
SG10201608525SA (en) 2016-12-29
PH12014502435A1 (en) 2015-01-12
AU2017202610B9 (en) 2019-06-20
ECSP14025178A (es) 2015-08-31
MX2014013200A (es) 2014-12-08
UA118336C2 (uk) 2019-01-10

Similar Documents

Publication Publication Date Title
BR112014027165A2 (pt) antagonistas de st2l e métodos de uso
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112017012621A2 (pt) peptídeos cíclicos com seletividade de ligação nervosa melhorada, nanopartículas ligadas com os referidos peptídeos cíclicos, e o uso dos mesmos para a produção de imagens de tecido nervoso in vivo em tempo real
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
EA201690087A1 (ru) Новые квиназолиноны как ингибиторы бромодомена
CY1120481T1 (el) Kv1.3 ανταγωνιστες και μεθοδοι χρησης
BR112015001841A2 (pt) filete ou listra de segurança, processo para fazer o mesmo ,substrato de segurança, processo para fazer o mesmo , uso do filete ou listra de segurança e documento de segurança.
FI20126341A (fi) Menetelmä mikrofibrilloidun selluloosan valmistamiseksi, josta vesi on poistettu
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
BR112015003927A2 (pt) filete ou listra de segurança, processo para fazer o filete ou listra de segurança, uso do filete ou listra de segurança, documento de segurança e processo para fazer o substrato de segurança.
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
BR112018002319A2 (pt) anticorpos anti-cd154 e métodos de uso dos mesmos
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
BR112013015005A2 (pt) corpo moldado contendo lignocelulose em multicamadas, processo para sua produção, e, uso do corpo moldado
BR112016010071A2 (pt) anticorpos anti-ccl17
BR112015017637A2 (pt) compósito plano, processo para produção de um compósito plano, recipiente, processo para a produção de um recipiente e uso de um compósito ou de um recipiente
BR112014005786A2 (pt) antagonistas do receptor do tipo toll 3 para o tratamento de doenças metabólicas e cardiovasculares
BR112015022975A2 (pt) partículas de resinato de fenilefrina
MX2015012381A (es) Inmunogenos fungicos y materiales y metodos relacionados.
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
BR112017003437A2 (pt) processo para a preparação e/ou purificação de cloreto de rutênio(iii)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time